You Searched For "Biogen" and got 20 results
Sort By:
1 min read
A 53-year-old biotech investor is set to be replaced by a 32-year-old exec on Biogen's board. No one disclosed that the new board member is his girlfriend and the mother of his child.
Susan Langer previously worked at Biogen and is the CEO of the biotech startup Souffle Therapeutics.
Zachary Tracer
4 mins read
We read through the 45-page congressional investigation into Biogen's Alzheimer's drug. Here are the 3 most shocking takeaways.
The investigation found that Biogen knew the drug's hefty price tag would make the medication inacc…
Yeji Jesse Lee,Leah Rosenbaum
3 mins read
Medicare sticks by decision to limit coverage of a controversial Alzheimer's drug to people involved in clinical trials
The Medicare coverage decision is a blow for Biogen, which has struggled with sales of its new drug…
Allison DeAngelis
2 mins read
Read the FDA report on the death of a woman who was taking a new Alzheimer's drug, reigniting safety concerns
These are Insider's biggest healthcare stories for December 13.
Leah Rosenbaum
2 mins read
The head of the FDA is calling for an investigation into her agency's controversial decision to approve a new Alzheimer's drug
The decision to approve Aduhelm has raised concerns and led three advisors to resign. The agency's …
Allison DeAngelis
2 mins read
The FDA approved a controversial, $56,000-a-year Alzheimer's drug despite opposition inside the agency, internal memos show
The director of the FDA's biostatistics office said there wasn't enough evidence to approve Aduhelm…
Allison DeAngelis
2 mins read
The 20 fastest-growing, highest-paying biotechs
These are Insider's biggest healthcare stories for June 21.
Lydia Ramsey Pflanzer
2 mins read
We just got the first new Alzheimer's drug in nearly 2 decades
These are Insider's biggest healthcare stories for June 8.
Lydia Ramsey Pflanzer
4 mins read
The FDA just approved the first new Alzheimer's drug in 18 years
The Food and Drug Administration approved Biogen's Alzheimer's disease treatment even though outsid…
Allison DeAngelis
1 min read
Biogen soars 13% on report of potential acquisition by South Korea's Samsung Group
Biogen could fetch a valuation of more than $42 billion, which would represent at least a 22% premi…
Matthew Fox
2 mins read
Investors are betting big on specialized primary care
These are Business Insider's biggest healthcare stories for February 2.
Lydia Ramsey Pflanzer
2 mins read
The FDA is delaying a controversial Alzheimer's drug decision. Analysts say that's a good sign.
The FDA has extended its deadline to approve or reject Biogen's drug by three months. Analysts say …
Allison DeAngelis
2 mins read
Biogen sinks 10% after Medicare limits coverage of new Alzheimer's drug Aduhelm
Medicare seeks to only cover patients who are enrolled in clinical trials evaluating Aduhelm, a dru…
Carla Mozée
1 min read
Biogen tanks 8% after Samsung denies report it was in talks to buy the drugmaker
Samsung's biotech division disputed the report in a filing in South Korea, calling it "not true," a…
Carla Mozée
3 mins read
Pfizer says its coronavirus vaccine works
These are Business Insider's biggest healthcare stories for November 9.
Lydia Ramsey Pflanzer
4 mins read
An election week for the history books
These are the top stories written by Business Insider's healthcare team for the week ending Novembe…
Lydia Ramsey Pflanzer
2 mins read
The promise of the first new Alzheimer's drug in nearly 2 decades
These are Business Insider's biggest healthcare stories for November 5.
Lydia Ramsey Pflanzer
1 min read
The 9 biotechs that stand to win after the FDA took a new approach to approving Biogen's Alzheimer's drug
These are Insider's biggest healthcare stories for June 9.
Lydia Ramsey Pflanzer
1 min read
A $44 billion biotech just got some good news from the FDA about a key Alzheimer's drug, and the stock is soaring
Biogen and Eisai said their experimental Alzheimer's treatment will be reviewed more quickly by reg…
Barbara Smith
2 mins read
Biogen falls 8% after 2 major hospital systems say they won't administer controversial Alzheimer's drug
The next big hurdle for Biogen will be receiving approval from health insurers to cover the costs o…